Hormonal implants: Contraception for a new century (original) (raw)

Abstract

Estrogen monotherapy and combined estrogen-progesto-May 1994 Am] Obstet Gynecol gen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomised cholesterol-fed rabbits.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (43)

  1. Croxatto H, Diaz S, Vera R, et al. Fertility control in women with a progestogen released in microquantities from subcutaneous capsules. Am j OBsrrr GYNECOL 1969; 105: 1135-8.
  2. Croxatto HB, Diaz S, Quinteros E, et al. Clinical assess- ment of subdermal implants of megestrol acetate, d-nor- gestrel, and norethindrone as a long-term contraceptive in women. Contraception 1975; 12: 615-27.
  3. Roy S, Mishell D, Robertson D, et al. Long-term reversible contraception with levonorgestrel-releasing Silastic rods. Am j OBsTFT GYNECOL 1984; 148: 1006-13.
  4. Haukkamaa M. Contraception by Norplant subdermal capsules is not reliable in epileptic patients on anticonvul- sant treatment. Contraception 1986; 33: 559-65.
  5. Diaz S, Herreros C, juez G, et al. Fertility regulation in nursing women: influence of Norplant levonorgestrel im- plants upon lactation and infant growth. Contraception 1985; 32: 53-74.
  6. Shaaban MM, Salem HT, Abdullah KA. Influence of levonorgestrel contraceptive implants, Norplant, initiated early postpartum, upon lactation and infant growth. Con- traception 1985; 32: 623-34.
  7. Darney PD, Klaisle CM, Tanner ST et al. Sustained release contraceptives. In: Ryan Kj, Barbiere RB, Berek JB, eds. Current problems in obstetrics, gynecology and fertility. Chicago: Mosby-Year Book, 1990: 87-125.
  8. Darney PD, Klaisle CM, Walker DM. The pop-out method of Not-plant removal. Adv Contracept 1992; 8: 188-9.
  9. Klavon SL, Grubb GS. Insertion site complications during the first year of Norplant use. Contraception 1990; 42: 27- 37.
  10. Alvarez F, Brache V, Tejada AS, et al. Abnormal endocrine profile among women with confirmed or presumed ovu- lation during long-term Norplant use. Contraception 1986; 33: 111-9.
  11. Faundes A, Brache V, Tejada AS, et al. Ovulatory dysfimc- tion during continuous administration of low-dose levonorgestrel by subdermal implants. Fertil Steril 1991; 56: 27-31.
  12. Brache V, Alvarez-Sanchez F, Faundes A, et al. Ovarian endocrine function through five years of continuous treat- ment with Norplant subdermal contraceptive implants. Contraception 1990; 41: 169-77.
  13. Brache V, Faundes A, johansson E, et al. Anovulation, inadequate luteal phase, and poor sperm penetration in cervical mucus during prolonged use of Norplant im- plants. Contraception 1985; 31: 261-78.
  14. Darney PD, Klaisle CM, Monroe SM, Walker DW. Effect of long-term Norplant use on the endometrium. Ann NY Acad Sci 1994 (in press).
  15. Segal S], Alvarez-Sanchez F, Brache V, et al. Norplant implants: the mechanism of contraceptive action. Fertil Steril 1991; 56-. 273-7.
  16. Sivin 1. International experience with Norplant and Nor- plant 2 contraceptives. Stud Fam Plann 1988; 19: 81-94.
  17. Sivin 1. Copper TIUD use and ectopic pregnancy rates in the United States. Contraception 1979; 19: 151-73.
  18. Franks AL, Beral V, Cates W jr, Hogue Cj. Contraception and ectopic pregnancy risk. Am j OB= GYNEcoL 1990; 163: 1120-5.
  19. Centers for Disease Control. Ectopic pregnancy in the United States, 1970-1988. MMWR CDC Surveill Summ 1989; 38: 1.
  20. Konje JCý Otolorin EO, Ladipo OA. Changes in carbohy- May 1994
  21. Am I Obstet Gynecol drate metabolism during 30 months on Norplant. Contra- ception 1991; 44: 163-71.
  22. Shaaban MM, Elwan ST, Sharkawy MM, et al. Effect of subdermal levonorgestrel contraceptive implants, Nor- plant, on liver functions. Contraception 1984; 30: 407-12.
  23. Shaaban MM, Elwan SI, Kabsch MY, et al. Effect of levonorgestrel contraceptive implants, Norplant, on blood coagulation. Contraception 1984; 30: 421-30.
  24. Abdulla KA, Elwan SI, Salem HS, et al. Effect of early postpartum use of the contraceptive implants, Norplant, on the serum levels of immunoglobulins of the mother and their breastfed infants. Contraception 1985; 32: 261-5.
  25. Bayad MA, Ibrahim 11, Fayad MM, et al. Serum cortisol in women users of subdermal levonorgestrel implants. Con- traceptive Delivery Systems 1983; 4: 133-5.
  26. Croxatto HB, Diaz S, Robertson DN, et al. Clinical chem- istry in women treated with levonorgestrel implants (Nor- plant) or a TCu 200 IUD. Contraception 1983; 27: 281-8.
  27. Croxatto HB, Diaz S, Pavez M. Clinical chemistry in women treated with progestogen implants. Contraception 1978; 18: 441-50.
  28. Affandi B, Suherman SK, DJaJalelana, et al. Serum lipids in Norplant implant users: a cross-sectional study. Con- traception 1987; 36: 429-34.
  29. Clarkson TB, Adams MR, Kaplan JR, et al. From men- arche to menopause: coronary artery atherosclerosis and protection in cynomolgus monkeys. Am J OBSTEr GYNECOL 1989-, 160: 1280.
  30. Sivin 1, Sanchez FA. Diaz S, et al. 1bree-year experience with Norplant subdermal contraception. Fertil Steril 1983; 39: 799-808.
  31. Shoupe D, Mishell DR, Bopp B, et al. The significance of bleeding patterns in Norplant implant users. Obstet Gy- necol 1991; 77: 256.
  32. Nilsson CG, Holma P. Menstrual blood loss with contra- ceptive subdermal levonorgestrel implants. Fertil Steril 1981; 35: 304-6.
  33. Alvarez F, Brache V, Faundes A. The clinical performance of Norplant implants over time: a comparison of two cohorts. Stud Fam Plann 1988; 19: 118-2 1.
  34. Sivin 1, Diaz S, Holma P, et al. A four-year clinical study of Norplant implants. Stud Fam Plann 1983; 14: 184-91.
  35. Diaz S, Pavez M, Cardenas H, et al. Recovery of fertility and outcome of planned pregnancies after the removal of Norplant subdermal implants or Copper-T IUDs. Contra- ception 1987; 35: 569-79.
  36. Sivin 1, Stem J, Diaz S, et al. Rates and outcomes of planned pregnancy after use of Norplant capsules, Nor- plant 11 rods, or levonorgestrel-releasing or Copper TCu 380Ag intrauterine contraceptive devices. Am J OBsTrr GYNECOL 1992; 166: 1208-13.
  37. Pardthaisong T. Return of fertility after use of the inject- able contraceptive Depo-Provera: updated analysis. J Bio- soc Sci 1984; 16: 23-8.
  38. Darney PD, Atkinson E, Tanner S, et al. Acceptance and perceptions of Norplant among users in San Francisco, USA. Stud Fam Plann 1990; 21: 152-60.
  39. Diaz S, Pavez M, Moo-Young AJ, et al. Clinical trial with 3-keto-desogestrel subdermal implants. Contraception 1991; 44: 393.
  40. Olsson S-E, Odlind V, Johansson E. Clinical results with subcutaneous implants containing 3-keto desogestrel. Contraception 1990; 42: 1.
  41. Geelen JAA, van der Wardt JTH, Voortman G, et al. Release kinetics of 3-keto-desogestrel from contraceptive implants (Implanon) in dogs: comparison with in vitro data. Contraception 1993; 47: 215-26.
  42. Haukkamaa M, Laurikka-Routti M, Heikinheimo 0, et al. Contraception with subdermal implant 's releasing the progestin ST-1435: a dose-finding study. Contraception 1992; 45: 49.
  43. Coutinho EM. One year contraception with a single sub-